AG0307OS/TROG08.07 - DECO - TROG Cancer Research

By w.paterson
15 August, 2021
0 Comments

"The DECO Study: A Randomised Phase II Trial of Weekly Docetaxel (Taxotere) Chemoradiotherapy +/- Cetuximab (Erbitux) in the Treatment of Localised Resectable Cancer of the Oesophagus."

Primary Sponsor

HeSANDA database for clinical trial data

21 April, 2025

Trial data-sharing made easier with HeSANDA initiative

Latest News: 21 April 2025 TROG Cancer Research is

16 April, 2025

Mark Hughes Foundation grant for innovative SMART trial into brain metastases

LATEST NEWS: 15 April 2025 An innovative trial aimed

For over 30 years, Trans-Tasman Radiation Oncology Group has been dedicated to improving the way radiation medicine is delivered to cancer patients with ongoing scientific research, clinical trials, and cutting-edge technology.

Quick Links

Legalities

"The DECO Study: A Randomised Phase II Trial of Weekly Docetaxel (Taxotere) Chemoradiotherapy +/- Cetuximab (Erbitux) in the Treatment of Localised Resectable Cancer of the Oesophagus."

MRC LU24/TROG 07.02 – QUARTZ

TROG 04.02 – Cervical – FIGO Stage & Tumour Volume

Related Post

Trial data-sharing made easier with HeSANDA initiative

Mark Hughes Foundation grant for innovative SMART trial into brain metastases

AG0307OS/TROG08.07 – DECO

"The DECO Study: A Randomised Phase II Trial of Weekly Docetaxel (Taxotere) Chemoradiotherapy +/- Cetuximab (Erbitux) in the Treatment of Localised Resectable Cancer of the Oesophagus."

MRC LU24/TROG 07.02 – QUARTZ

TROG 04.02 – Cervical – FIGO Stage & Tumour Volume

Related Post

Trial data-sharing made easier with HeSANDA initiative

Mark Hughes Foundation grant for innovative SMART trial into brain metastases